Amexis Georgios, Young Neal S
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
Viral Immunol. 2007 Dec;20(4):657-63. doi: 10.1089/vim.2007.0029.
Dengue is an important agent of human disease for which no licensed vaccine is available to the public. We used multiple antigenic peptides (MAPs) as an antigen carrier for the development of subunit vaccines against dengue-2 virus (DEN-2). Commercially available software (MacVector 7.0) was used to identify potential antigenic B-cell epitopes of E-glycoprotein. A total of 60 BALB/c mice were immunized with 12 recombinant DEN-2-specific MAPs and the humoral immune response was assessed by anti-DEN-2 ELISA and PRNT50 assays. Anti-DEN-2 ELISA showed high levels of anti-DEN-2 antibodies and post-immune sera reduced viral infectivity and prevented infection of monkey kidney cells (LLC-MK2) with live DEN-2 virus. Seven neutralizing DEN-2 epitopes were identified that generated PRNT50 titers of up to 1:160. Our findings show that the MAP platform can be used as an antigen-presenting platform for dengue vaccine development.
登革热是一种重要的人类疾病病原体，目前尚无面向公众的许可疫苗。我们使用多种抗原肽（MAPs）作为抗原载体来开发针对登革热2型病毒（DEN-2）的亚单位疫苗。利用市售软件（MacVector 7.0）来鉴定E糖蛋白潜在的抗原性B细胞表位。用12种重组DEN-2特异性MAPs免疫60只BALB/c小鼠，并通过抗DEN-2 ELISA和PRNT50试验评估体液免疫反应。抗DEN-2 ELISA显示出高水平的抗DEN-2抗体，免疫后血清降低了病毒感染性，并预防了活DEN-2病毒对猴肾细胞（LLC-MK2）的感染。鉴定出7个中和DEN-2表位，其产生的PRNT50效价高达1:160。我们的研究结果表明，MAP平台可作为登革热疫苗开发的抗原呈递平台。
